Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
CLDN25 Biologics Sequence Review Report 2026: Claudin-25 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN25 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CLDN24 Biologics Sequence Review Report 2026: Claudin-24 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN24 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CLDN23 Biologics Sequence Review Report 2026: Claudin-23 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN23 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CLDN22 Biologics Sequence Review Report 2026: Claudin-22 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN22 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CLDN19 Biologics Sequence Review Report 2026: Claudin-19 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN19 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CLDN17 Biologics Sequence Review Report 2026: Claudin-17 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN17 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CLDN20 Biologics Sequence Review Report 2026: Claudin-20 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN20 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CLDN16 Biologics Sequence Review Report 2026: Claudin-16 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN16 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CLDN14 Biologics Sequence Review Report 2026: Claudin-14 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN14 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CLDN15 Biologics Sequence Review Report 2026: Claudin-15 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN15 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CLDN11 Biologics Sequence Review Report 2026: Claudin-11 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN11 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CLDN10 Biologics Sequence Review Report 2026: Claudin-10 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN10 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
<
1
<<
1162
1163
1164
1165
1166
>>
2926
>